BrAin Metastasis in TripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC

PHASE2RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Triple-Negative Breast Cancer (TNBC)Brain Metastases
Interventions
DRUG

Ivonescimab Combined With TROP2 ADC

Ivonescimab: 20 mg/kg, ivggt, day 1, every 3 weeks; Sacituzumab govitecan: 10 mg/kg, ivggt, day 1 and day 8, every 3 weeks;

Trial Locations (1)

China 200032

RECRUITING

Fudan University Shanghai Cancer center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER